MO-0722 Radiation dose-escalation for glioblastoma: who may benefit? von Trip, A., Møller Hochreuter, K., Høyer, M., Folsted Kallehauge, J., Lukacova, S.

Volltext

PD-0805 Diffusion kurtosis imaging and white matter injury after radiotherapy of adults with brain tumours von Skinnerup Byskov, C., Haldbo-Classen, L., Harbøll, A., Nørhøj Jespersen, S., Folsted Kallehauge, J.

Volltext

PO-1682 Visibility, artifacts and dose degradations around gold markers in proton therapy of prostate cancer von Stolarczyk, L., Folsted Kallehauge, J., Barbosa Valdetaro, L., Muren, L.P., Høyer, M., Randers, P., Stagaard Johansen, T., Rønde, H.S., Sitarz, M., Tilbæk, S., Vestergaard, A., Bentzenb, L., Elleberg Petersena, S.

Volltext

OC-0418 European multi-centric study on variable proton RBE dose calculations for multiple anatomical sites von Hahn, C., Ödén, J., Dasu, A., Vestergaard, A., Folsted Kallehauge, J., Pardi, C., Bourhaleb, F., Leite, A., de Marzi, L., Smith, E., Aitkenhead, A., Merchant, M., Kirkby, K., Troost, E.G.C., Lühr, A.

Volltext

PD-0242 Parameters driving oncologists’ selection of glioma grade 2 and 3 patients for proton therapy von Skinnerup Byskov, C., Rønn Hansen, C., Hedegaard Dahlrot, R., Dysager, L., Lignell Guldberg, T., Haldbo-Classen, L., Hansen, S., Aaquist Haslund, C., Høyer, M., Lukacova, S., Muhic, A., Witt Nyström, P., Ramshad-Lassen, Y., Kirsten Trip, A., Weber, B., Folsted Kallehauge, J.

Volltext